GLP-1 drugs have reshaped how chronic kidney disease is approached in patients with type-2 diabetes and obesity. The FLOW trial gave semaglutide a CKD outcomes label, and the REMODEL trial — presented at the 2026 World Congress of Nephrology — added mechanistic data showing that semaglutide decreased renal fat, lowered arterial resistance, and stabilized cortical fibrosis. Biopsies revealed reduced immune cells around glomeruli, and transcriptomic analysis identified glomerular endothelial cells as the most responsive cell type. The full paper, published in Nature Medicine on October 1, 2026, showed that the coprimary MRI measures of kidney oxygenation, perfusion, and inflammation did not change significantly versus placebo; the vascular and scarring findings were secondary outcomes.
The story has expanded: GLP-1s now have heart, kidney, and metabolic indications often pursued in the same patient. Cardiometabolic peptide candidates outside the GLP-1 class — Takeda's rusfertide for polycythemia vera, Merck's PCSK9 work — also land here.
Stories cover trial readouts, mechanism papers, and payer rulings. See #cardiovascular and #nephrology.
Researchers at Hebrew University and Hadassah Medical Center reported in Diabetes, Obesity and Metabolism on October 7, 2026 a records study of 4,554 matched adults with type 2 diabetes and stage 3 or 4 chronic kidney disease who started a GLP-1 drug or tirzepatide, or finerenone, a non-steroidal kidney drug. Kidney failure or dialysis occurred in 4.8% versus 6.0% within 2.5 years (hazard ratio 0.71), but the absolute risk difference of 1.14 percentage points was not statistically clear. Albuminuria, a key kidney measure, was missing for most people, so the authors warned of residual confounding.
Full results of Novo's REMODEL trial, first presented at the 2026 World Congress of Nephrology, were published in Nature Medicine on Thursday, October 1, 2026. The trial randomized 106 adults with type 2 diabetes and chronic kidney disease to semaglutide 1 mg weekly or placebo for 52 weeks to learn how the drug protects the kidneys. Its coprimary MRI measures of kidney oxygenation, perfusion, and inflammation did not change significantly versus placebo, but semaglutide lowered the renal artery resistive index and kept stable an MRI marker the authors link to scarring, and paired biopsies showed marked effects on the cells lining the kidney's filtering blood vessels, with fewer immune cells nearby. Urine albumin fell 40% in an exploratory analysis; Novo Nordisk funded the trial.
The ADA closed its 86th Scientific Sessions on June 8 with a formal revision to its Standards of Care that elevates cardiovascular and kidney risk reduction to a co-primary treatment goal alongside glycemic control, ending decades of practice in which HbA1c stood as the dominant benchmark. The shift formalizes a redefinition of diabetes care around the cardio-renal-metabolic axis that GLP-1, SGLT2, and finerenone evidence has driven, and pushes earlier GLP-1 and SGLT2 use from diabetes diagnosis.
A Frontiers in Endocrinology multicenter retrospective cohort study (2026) reports real-world safety and effectiveness of semaglutide in patients with type 2 diabetes and end-stage renal disease — the population systematically excluded from FLOW (which capped at eGFR ≥ 25) and the SELECT pre-specified kidney composite analysis. ESRD patients comprise roughly 1% of the diabetic population but 7% of US healthcare spending; their cardiovascular event rates are among the highest documented. The cohort fills a clinical gap: prescribers managing dialysis-dependent patients have had to extrapolate from outcome trials that explicitly excluded the population. Work joins the SOUL oral-semaglutide CKD analysis as the fastest-growing GLP-1 evidence stream beyond obesity and T2D.
Mechanistic data from the REMODEL trial presented at the 2026 World Congress of Nephrology showed semaglutide decreased renal fat, lowered arterial resistance, and stabilized cortical fibrosis. Biopsies revealed reduced immune cells around glomeruli, and transcriptomic analysis identified glomerular endothelial cells as the most responsive cell type to treatment.
The FLOW trial showed semaglutide reduced major kidney disease events by ~24%, while the SELECT trial found a 20% reduction in major adverse cardiovascular events among 17,600+ adults.
At APhA2026, semaglutide's FLOW trial showed 24% reduction in major kidney events in CKD patients, while tirzepatide's SURMOUNT-OSA trial demonstrated dramatic reductions in sleep apnea severity.